BR112013006355A2 - profármacos de éster de [3-(1-(1h-imidazol-4-il)etil-2-metilfenil] metanol para tratar doenças retinais - Google Patents

profármacos de éster de [3-(1-(1h-imidazol-4-il)etil-2-metilfenil] metanol para tratar doenças retinais

Info

Publication number
BR112013006355A2
BR112013006355A2 BR112013006355A BR112013006355A BR112013006355A2 BR 112013006355 A2 BR112013006355 A2 BR 112013006355A2 BR 112013006355 A BR112013006355 A BR 112013006355A BR 112013006355 A BR112013006355 A BR 112013006355A BR 112013006355 A2 BR112013006355 A2 BR 112013006355A2
Authority
BR
Brazil
Prior art keywords
imidazol
methylphenyl
ethyl
retinal diseases
ester prodrugs
Prior art date
Application number
BR112013006355A
Other languages
English (en)
Inventor
Daniel W Gil
John E Donello
Ken Chow
Liming Wang
Micahel E Garst
Mohammed I Dibas
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013006355(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112013006355A2 publication Critical patent/BR112013006355A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

profármacos de éster de [3-(1-(1h-imidazol-4-il)etil-2-metilfenil] metanol para tratar doenças retinais. a presente invenção refere-se a método de tratar doenças retinais em um indivíduo em necessidade de tal tratamento, que compreende administrar uma quantidade terapeuticamente eficaz de uma composição compreendendo profármacos de éster de [3-1(01h-imidazol-4-il)etil)-2-metilfenil] metanol, processos para prepará-los, composições farmacêuticas contendo-os e seus usos como produtos farmacêuticos.
BR112013006355A 2010-09-16 2011-09-16 profármacos de éster de [3-(1-(1h-imidazol-4-il)etil-2-metilfenil] metanol para tratar doenças retinais BR112013006355A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16
PCT/US2011/051926 WO2012037453A1 (en) 2010-09-16 2011-09-16 Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

Publications (1)

Publication Number Publication Date
BR112013006355A2 true BR112013006355A2 (pt) 2016-06-28

Family

ID=44675870

Family Applications (4)

Application Number Title Priority Date Filing Date
BR112013006362A BR112013006362A2 (pt) 2010-09-16 2011-09-16 uso de compostos profármacos de éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol para reduzir a pressão intraocular, composição farmacêutica e artigo de fabricação
BR112013006352A BR112013006352A2 (pt) 2010-09-16 2011-09-16 profármacos compostos profármacos de éster de [3-(1 -{1h-imidazol-4-il)etil)-2-metilfenil] metanol para tratar doenças e condições da pele, composição farmacêutica e artigo de fabricação
BR112013006355A BR112013006355A2 (pt) 2010-09-16 2011-09-16 profármacos de éster de [3-(1-(1h-imidazol-4-il)etil-2-metilfenil] metanol para tratar doenças retinais
BR112013006320-3A BR112013006320B1 (pt) 2010-09-16 2011-09-16 Composto, composição farmacêutica e seu uso

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR112013006362A BR112013006362A2 (pt) 2010-09-16 2011-09-16 uso de compostos profármacos de éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol para reduzir a pressão intraocular, composição farmacêutica e artigo de fabricação
BR112013006352A BR112013006352A2 (pt) 2010-09-16 2011-09-16 profármacos compostos profármacos de éster de [3-(1 -{1h-imidazol-4-il)etil)-2-metilfenil] metanol para tratar doenças e condições da pele, composição farmacêutica e artigo de fabricação

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112013006320-3A BR112013006320B1 (pt) 2010-09-16 2011-09-16 Composto, composição farmacêutica e seu uso

Country Status (29)

Country Link
US (9) US8492422B2 (pt)
EP (13) EP2616068B1 (pt)
JP (4) JP6073229B2 (pt)
KR (7) KR102139905B1 (pt)
CN (5) CN103200942A (pt)
AR (4) AR083019A1 (pt)
AU (4) AU2011301847B2 (pt)
BR (4) BR112013006362A2 (pt)
CA (8) CA3122745A1 (pt)
CL (4) CL2013000735A1 (pt)
CY (3) CY1121024T1 (pt)
DK (9) DK2616068T3 (pt)
ES (10) ES2684055T3 (pt)
HK (5) HK1185539A1 (pt)
HU (5) HUE047476T2 (pt)
IL (4) IL225282A0 (pt)
MX (4) MX2013003008A (pt)
MY (4) MY173846A (pt)
NZ (1) NZ608751A (pt)
PL (7) PL3050564T3 (pt)
PT (7) PT3053576T (pt)
RU (4) RU2013116405A (pt)
SG (4) SG188570A1 (pt)
SI (5) SI3338777T1 (pt)
TR (1) TR201909249T4 (pt)
TW (4) TW201240661A (pt)
UA (1) UA112973C2 (pt)
WO (4) WO2012037484A1 (pt)
ZA (4) ZA201302193B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010213580A1 (en) * 2009-02-13 2011-09-08 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
BR112014001501A2 (pt) * 2011-07-22 2017-02-14 Allergan Inc moduladores alfa-2 adrenérgicos para tratamento de distúrbios visuais mediados por projeções visuais centrais do olho
EP2782569A1 (en) 2011-11-21 2014-10-01 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
CA3110436C (en) * 2018-08-24 2023-09-26 Adlai Nortye Biopharma Co., Ltd. High activity sting protein agonist
AU2022258105A1 (en) * 2021-04-16 2023-10-26 Ads Therapeutics Llc Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023010A1 (en) 1992-05-13 1993-11-25 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
AU693142B2 (en) 1993-11-15 1998-06-25 Schering Corporation Phenyl-alkyl imidazoles as H3-receptor antagonists
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
WO2004106307A2 (fr) * 2003-05-27 2004-12-09 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament
JP2007528020A (ja) * 2003-07-14 2007-10-04 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 投影装置
CN102657664A (zh) 2003-09-12 2012-09-12 阿勒根公司 用于治疗疼痛和其它α2肾上腺素能介导疾病的方法及组合物
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
NZ552325A (en) * 2004-05-25 2010-11-26 Sansrosa Pharmaceutical Dev Inc The use of alpha 2 andrenoceptor agonists such as brimonidine for treating inflammatory skin disorders
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
BRPI0516083A (pt) * 2004-09-24 2008-08-19 Allergan Sales Inc 4-(fenilmetil e 4-fenilmetil substituìdo)-imidazol-2-tionas que atuam como agonistas alfa2 adrenérgicos
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
CA2751651A1 (en) 2009-02-06 2010-08-12 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
AU2010213580A1 (en) * 2009-02-13 2011-09-08 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions

Also Published As

Publication number Publication date
EP3348264B1 (en) 2020-01-01
IL225282A0 (en) 2013-06-27
EP3078376B1 (en) 2019-03-27
PT3348264T (pt) 2020-04-02
ES2904479T3 (es) 2022-04-05
AU2011301901B2 (en) 2016-02-11
HUE038698T2 (hu) 2018-11-28
HUE039090T2 (hu) 2018-12-28
KR101952457B1 (ko) 2019-02-26
PT3053576T (pt) 2018-10-08
US20120142746A1 (en) 2012-06-07
HK1185541A1 (zh) 2014-02-21
ES2593612T3 (es) 2016-12-12
RU2013116405A (ru) 2014-10-27
SG188572A1 (en) 2013-04-30
ZA201302288B (en) 2013-11-27
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
AR083019A1 (es) 2013-01-23
JP2013537236A (ja) 2013-09-30
RU2013116403A (ru) 2014-10-27
HK1185540A1 (zh) 2014-02-21
ES2781681T3 (es) 2020-09-04
CA2811559A1 (en) 2012-03-22
MY191369A (en) 2022-06-20
DK3078376T3 (da) 2019-06-24
CN103200941B (zh) 2015-12-16
EP3659600A1 (en) 2020-06-03
KR102354097B1 (ko) 2022-01-20
ZA201302193B (en) 2013-11-27
US8492557B2 (en) 2013-07-23
US20130296394A1 (en) 2013-11-07
DK3338777T3 (da) 2020-04-20
KR101840500B1 (ko) 2018-03-20
DK3636263T3 (da) 2022-01-10
IL225281A0 (en) 2013-06-27
EP3078376A1 (en) 2016-10-12
DK3050563T3 (en) 2018-08-13
NZ608751A (en) 2015-04-24
CY1121024T1 (el) 2019-12-11
PT3050564T (pt) 2019-12-11
AR083020A1 (es) 2013-01-23
PL3348264T3 (pl) 2020-08-24
BR112013006352A2 (pt) 2016-06-28
WO2012037484A1 (en) 2012-03-22
CL2013000735A1 (es) 2013-11-29
ZA201302194B (en) 2013-11-27
CL2013000734A1 (es) 2013-11-08
EP2616069A1 (en) 2013-07-24
RU2612351C2 (ru) 2017-03-07
PT3338777T (pt) 2020-05-06
MY161607A (en) 2017-04-28
SI3053576T1 (sl) 2018-11-30
CY1122809T1 (el) 2021-05-05
JP6045495B2 (ja) 2016-12-14
ES2607084T3 (es) 2017-03-29
IL225280A0 (en) 2013-06-27
PL3053576T3 (pl) 2018-11-30
ES2687420T3 (es) 2018-10-25
HK1257416A1 (zh) 2019-10-18
ES2788051T3 (es) 2020-10-20
DK3348264T3 (da) 2020-03-23
EP3050564B1 (en) 2019-09-04
AU2011301856A1 (en) 2013-05-02
DK2616068T3 (en) 2016-08-29
JP2013537237A (ja) 2013-09-30
CA2812191A1 (en) 2012-03-22
AU2011301932C1 (en) 2016-09-01
MX2013003009A (es) 2013-06-28
EP3338777A1 (en) 2018-06-27
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
CA3122745A1 (en) 2012-03-22
TW201240662A (en) 2012-10-16
CL2013000733A1 (es) 2013-08-23
PL2616068T3 (pl) 2016-11-30
CA2812191C (en) 2021-04-13
KR20200091507A (ko) 2020-07-30
PL3050564T3 (pl) 2020-06-01
KR102104760B1 (ko) 2020-04-27
EP2616067B1 (en) 2016-05-18
WO2012037490A1 (en) 2012-03-22
WO2012037499A1 (en) 2012-03-22
KR101840501B1 (ko) 2018-05-04
US20160354346A1 (en) 2016-12-08
US8492422B2 (en) 2013-07-23
US8853251B2 (en) 2014-10-07
US20150148394A1 (en) 2015-05-28
EP3636263A1 (en) 2020-04-15
AU2011301847A1 (en) 2013-05-02
PT2616068T (pt) 2016-09-13
AU2011301856C1 (en) 2016-09-08
EP3348264A1 (en) 2018-07-18
TR201909249T4 (tr) 2019-07-22
EP2616069B1 (en) 2016-11-16
SI3050563T1 (sl) 2018-10-30
SI3050564T1 (sl) 2020-02-28
CA2812197C (en) 2024-01-02
CN105412092B (zh) 2020-11-17
PT3050563T (pt) 2018-10-01
SG188570A1 (en) 2013-04-30
IL225278A0 (en) 2013-06-27
JP2013540749A (ja) 2013-11-07
MX2013003008A (es) 2013-06-28
HUE047476T2 (hu) 2020-04-28
CN103200942A (zh) 2013-07-10
US20120149746A1 (en) 2012-06-14
EP3050564A1 (en) 2016-08-03
MX2013003002A (es) 2013-06-28
EP2616066B1 (en) 2016-07-13
US8653123B2 (en) 2014-02-18
TW201305116A (zh) 2013-02-01
US20120122945A1 (en) 2012-05-17
EP2616068B1 (en) 2016-07-13
HK1185538A1 (zh) 2014-02-21
EP3698789A1 (en) 2020-08-26
PL3338777T3 (pl) 2020-07-13
BR112013006320A2 (pt) 2016-06-21
SG188573A1 (en) 2013-04-30
ES2684055T3 (es) 2018-10-01
DK3050564T3 (da) 2019-11-25
CN103200941A (zh) 2013-07-10
EP3636263B1 (en) 2021-11-03
AU2011301901A1 (en) 2013-05-02
AU2011301932B2 (en) 2016-02-25
BR112013006320B1 (pt) 2022-08-30
MX2013003004A (es) 2013-06-28
TWI591058B (zh) 2017-07-11
US20140057958A1 (en) 2014-02-27
EP2616066A1 (en) 2013-07-24
JP6073229B2 (ja) 2017-02-01
PL3050563T3 (pl) 2018-12-31
AR083018A1 (es) 2013-01-23
CN105412092A (zh) 2016-03-23
CL2013000736A1 (es) 2013-07-12
DK2616069T3 (en) 2016-12-19
US20130289088A1 (en) 2013-10-31
US8501796B2 (en) 2013-08-06
CN103221045A (zh) 2013-07-24
EP3053576A1 (en) 2016-08-10
JP2013541527A (ja) 2013-11-14
UA112973C2 (uk) 2016-11-25
TW201240661A (en) 2012-10-16
KR20200044147A (ko) 2020-04-28
SI3348264T1 (sl) 2020-07-31
MY168763A (en) 2018-12-04
EP3053576B1 (en) 2018-05-16
KR20140005154A (ko) 2014-01-14
ZA201302291B (en) 2013-11-27
WO2012037453A1 (en) 2012-03-22
CA2812197A1 (en) 2012-03-22
AU2011301932A1 (en) 2013-05-02
EP3338777B1 (en) 2020-02-05
ES2737230T3 (es) 2020-01-10
RU2013116541A (ru) 2014-10-27
PT2616069T (pt) 2016-12-06
PL2616069T3 (pl) 2017-04-28
HUE048725T2 (hu) 2020-09-28
SG188571A1 (en) 2013-04-30
TW201305117A (zh) 2013-02-01
EP2616067A1 (en) 2013-07-24
HK1185539A1 (zh) 2014-02-21
CN103209694A (zh) 2013-07-17
CA3116249A1 (en) 2012-03-22
MY173846A (en) 2020-02-24
CA3079450A1 (en) 2012-03-22
EP2616068A1 (en) 2013-07-24
EP3050563A1 (en) 2016-08-03
KR20190022895A (ko) 2019-03-06
CA2812195A1 (en) 2012-03-22
CY1122958T1 (el) 2021-10-29
SI3338777T1 (sl) 2020-08-31
ES2760920T3 (es) 2020-05-18
ES2613509T3 (es) 2017-05-24
IL225278A (en) 2015-11-30
EP3050563B1 (en) 2018-05-09
HUE049573T2 (hu) 2020-10-28
KR20130114140A (ko) 2013-10-16
DK3053576T3 (en) 2018-08-20
KR20140003407A (ko) 2014-01-09
US20120136036A1 (en) 2012-05-31
AU2011301847B2 (en) 2016-02-11
KR102139905B1 (ko) 2020-07-31
CA3077732A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
BR112013006355A2 (pt) profármacos de éster de [3-(1-(1h-imidazol-4-il)etil-2-metilfenil] metanol para tratar doenças retinais
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
PH12015501404B1 (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
BR112012023021A2 (pt) compostos de indazol e seus usos
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
BR112012016879A2 (pt) Derivados de fumarato de acido graxo e seus usos
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
DOP2012000225A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
CL2012001714A1 (es) Compuestos derivados de pirrol[3.4-b]piridin-5-ona, inhibidores de pi3k; composicion farmaceutica que los comprende; y uso para el tratamiento de enfermedades tales como alzheimer, epilepsia, esclerosis multiple, parkinson, entre otras.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
BR112014027942A2 (pt) dispersão de pó pró-lipossomal; composição farmacêutica; forma de dosagem oral; e método para tratar um indivíduo que necessite de terapia de testosterona
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
BR112015003729A8 (pt) Composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
WO2012170918A3 (en) Methods of treatment for retinal diseases
UA106353C2 (en) Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs
BR112013032911A2 (pt) leucotoxina e/d como um novo agente anti-inflamatório e microbicida
UA112418C2 (uk) Терапевтичний болезаспокійливий засіб
BR112012025879A2 (pt) compostos de triazol como inibidores de ksp
BR112014005966A2 (pt) composições para o tratamento de úlceras periféricas de várias origens
UA112981C2 (uk) Варіант людського gdnf
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
BR112013033807A2 (pt) formulações pirroloquinolinil-pirrolidin-2,5-diona e métodos para sua preparação

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.